A gene expression signature associated with survival in metastatic melanoma

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Mandruzzato, Susanna ^a   Callegaro, Andrea ^a   Turcatel, Gianluca ^a   Francescato, Samuela ^a   Montesco, Maria C ^a   Chiarion Sileni, Vanna ^b   Mocellin, Simone ^a   Rossi, Carlo R ^a   Bicciato, Silvio ^a   Wang, Ena ^c   Marincola, Francesco M ^c   Zanovello, Paola ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RNA;

ACCURACY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALE; MELANOMA; METASTASIS; PROGNOSIS; RNA EXTRACTION; SURVIVAL TIME;

EID: 33845783311     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-50     Document Type: Article

References (44)

1. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
2. Homsi J, Kashani-Sabet M, Messina JL, Daud A: Cutaneous melanoma: prognostic factors. Cancer Control 2005, 12:223-229.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
4. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
5. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M: Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer 1999, 86:288-299.
6. Byers HR, Bhawan J: Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Hematol Oncol Clin North Am 1998, 12:717-735.
7. Busam KJ: The use and application of special techniques in assessing melanocytic tumours. Pathology 2004, 36:462-469.
8. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
9. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
10. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
11. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
12. Carr KM, Bittner M, Trent JM: Gene-expression profiling in human cutaneous melanoma. Oncogene 2003, 22:3076-3080.
13. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
14. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M: The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005, 102:6092-6097.
15. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM: Melanoma-restricted genes. J Transl Med 2004, 2:34.
16. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E: Common cancer biomarkers. Cancer Res 2006, 66:2953-2961.
17. [http://nciarray.nci.nih.gov/gal_files/index.shtml].
18. [http://linus.nci.nih.gov/BRB-ArrayTools.html].
19. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121.
20. [http://www-stat.stanford.edu/~tibs/SAM/].
21. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004, 2:E108.
22. [http://www-stat.stanford.edu/~tibs/superpc/].
23. Gui J, Li H: Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics 2005, 21:3001-3008.
24. Nguyen DV, Rocke DM: Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 2002, 18:1625-1632.
25. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988, 48:1019-1025.
26. Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, Parmiani G: Classes I and II HLA and mellanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 1986, 46:433-439.
27. Jamieson S, Going JJ, D'Arcy R, George WD: Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J Pathol 1998, 184:37-43.
28. Ito A, Koma Y, Uchino K, Okada T, Ohbayashi C, Tsubota N, Okada M: Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: Significant correlation with poor prognosis. Cancer Lett 2006, 234(2):239-48.
29. Bumol TF, Reisfeld RA: Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A 1982, 79:1245-1249.
30. Olsen EB, Trier K, Eldov K, Ammitzboll T: Glycosaminoglycans in human breast cancer. Acta Obstet Gynecol Scand 1988, 67:539-542.
31. Held-Feindt J, Paredes EB, Blomer U, Seidenbecher C, Stark AM, Mehdorn HM, Mentlein R: Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 2006, 118:55-61.
32. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, Kim TE, Kim JW: Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res 2004, 10:8386-8395.
33. Nishioka E, Funasaka Y, Kondoh H, Chakraborty AK, Mishima Y, Ichihashi M: Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis. Melanoma Res 1999, 9:433-443.
34. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
35. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004, 164:193-203.
36. Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Hakansson A: On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 2003, 88:424-431.
37. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104:1246-1254.
38. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD: Interleukin-4 and interleukin-13 signaling connections maps. Science 2003, 300:1527-1528.
39. Obiri NI, Siegel JP, Varricchio F, Puri RK: Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 1994, 95:148-155.
40. Brass N, Racz A, Heckel D, Remberger K, Sybrecht GW, Meese EU: Amplification of the genes BCHE and SLC2A2 in 40% of squamous cell carcinoma of the lung. Cancer Res 1997, 57:2290-2294.
41. Soreq H, Lapidot-Lifson Y, Zakut H: A role for cholinesterases in tumorigenesis? Cancer Cells 1991, 3:511-516.
42. Ishimi Y, Okayasu I, Kato C, Kwon HJ, Kimura H, Yamada K, Song SY: Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem 2003, 270:1089-1101.
43. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004, 165:881-891.
44. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.